Morepen Laboratories Reports 69% Surge in Q4 Net Profit; CDMO Program Moves to Commercial Phase

Morepen Laboratories Reports 69% Surge in Q4 Net Profit; CDMO Program Moves to Commercial Phase​

Gurugram, May 27, 2026: Morepen Laboratories Limited reported a robust performance for the fourth quarter of FY26, noting a 69% year-over-year rise in net profit to Rs. 20 crore. The company also announced that its major global CDMO mandate has commenced commercial execution. Furthermore, the Board has proposed a 10% dividend for shareholders for FY26.

The strong quarterly results were driven by export momentum and significant expansion within the Medical Devices segment, accelerating operational momentum throughout the latter part of the financial year.

Quarterly Financial Highlights​

The company reported substantial growth metrics during the quarter, alongside strong full-year performance:


Additionally, the standalone gross revenue for FY26 crossed Rs. 1,700 crore, representing an 8% increase. EBITDA for Q4 FY26 stood at Rs. 32 crore, compared to Rs. 33 crore in Q4 FY25.

Strategic Program Execution and Growth Initiatives​

A key development is the commencement of commercial production under Morepen's long-duration manufacturing partnership program. This initiative is backed by a multi-year global CDMO mandate valued at Rs. 825 crore or USD 91 million, secured in February 2026 from a leading global multinational.

The company is actively expanding its manufacturing capabilities, scaling capacity from approximately 500 KL toward 800 KL, with a longer-term roadmap extending towards 1,000 KL.

The Medical Devices platform also continues to scale strongly. For FY26, the revenue generated by this segment grew 21% to Rs. 598 crore, maintaining an installed base of nearly 17 million repeat users. The company is developing this platform as a separate high-growth healthcare business focused on chronic care, consumer diagnostics, CGM opportunities, and connected healthcare integration.

Operational milestones supporting the company’s growth include completing its fourth consecutive USFDA inspection with zero 483 observations.

Strategic Direction and Future Platforms​

Mr. Sushil Suri, Chairman & Managing Director, stated that Morepen has built strong manufacturing capabilities and global customer relationships, noting that the company is entering a new growth phase focused on long-duration manufacturing partnerships and scale expansion.

He added that the business is evolving from a traditional API model towards a manufacturing-led platform, supported by recurring revenues, process scale-up, and regulated-market partnerships.

Mr. Sanjay Suri, Executive Director and CEO - API, commented on the expansion, stating that increasing scale, improving the product mix, and implementing long-duration supply programs are expected to support stronger margins and clearer earnings visibility in the medium term.

Further advancing its specialty pipeline, the company successfully completed a pivotal bioequivalence study for Resmetirom 100 mg, an oral thyroid hormone receptor-beta agonist used in the treatment of moderate to advanced liver fibrosis associated with MASH, covering major regulated markets outside the US.

Strategic investments in manufacturing scale-up, Devices expansion, and customer acquisition are expected to support operating leverage, margin expansion, and stronger long-term earnings visibility.

MOREPENLAB Stock Price Movement​

On Tuesday, Morepen Laboratories Limited shares gained 1.10%, closing higher at ₹43.92. The equity saw significant investor interest, handling a total volume of 4.55 million shares during the session.